Meta-Analysis · August 2024
412 total participants pooled RCTs Middle-aged & elderly Peer-reviewed "NMN has positive efficacy in enhancing muscle function, reducing insulin resistance, and lowering aminotransferase levels in middle-aged and elderly individuals. NMN had significant effects on muscle mass and gait speed."
65 participants, Avg age 34.714 days, 1,000 mg/day Randomised open-label RCTNMN supplementation doubled circulating NAD+ concentrations in healthy adults within 14 days, outperforming NAM (standard niacinamide) which showed no significant NAD+ increase.
80 participants, ages 40–6560 days 300 / 600 / 900 mg/day. Multi-centre double-blind RCTNMN significantly raised blood NAD+ at all doses. The 900 mg group showed the strongest health score improvements — the 300 mg group improved walking speed by 24%, the 600 and 900 mg groups by 50%. Published in Geroscience.
48 participants, ages 27–506 weeks 300 / 600 / 1200 mg/day. Double-blind RCTNMN significantly improved VO₂max and endurance in trained recreational runners. Higher doses produced greater improvements in oxygen utilisation. Published in the Journal of the International Society of Sports Nutrition.
Ages 65–7512 weeks 250 mg/day. Randomised placebo-controlled double-blind. After 12 weeks, the NMN group had significantly faster 4-metre walking speed and improved sleep quality versus placebo. Blood NAD+ and its metabolites also rose significantly, confirming real bioavailability in older adults.
31 participants, ages 20–654 weeks 1,250 mg/day Double-blind placebo-controlled RCTOral NMN at 1,250 mg/day did not result in any changes exceeding physiological norms across hematological, biochemical, urine, and body composition analyses. Confirmed safe even at high doses with no adverse effects.
25 participants, Prediabetic postmenopausal women, 10 weeks, 250 mg/day, Washington Univ. double-blind RCT. Skeletal muscle insulin sensitivity improved by approximately 25%. First study to demonstrate a real metabolic benefit of NMN in humans. NMN also upregulated genes involved in energy metabolism and muscle remodelling. Published in Science, 2021.
NAD+ & Well-being · Feb 2023
36 participants, Healthy middle-aged, 12 weeks, 250 mg twice daily. Double-blind placebo-controlled RCTNAD+-boosting supplementation with NMN showed significant improvements in well-being markers and blood NAD+ levels over 12 weeks in healthy middle-aged participants.
437 total patients, 10 RCTs included. Mean age 58 years. Mean follow-up 9.6 weeks. Dosage 150–1,200 mg/day PRISMA-guideline review · PubMed / NCBIAcross 437 patients, NMN consistently improved physical performance parameters, including muscle strength, endurance, and mobility. The safety profile was confirmed as excellent across all dose ranges (150–1,200 mg/day) with no severe adverse events reported in any included study.
